NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) insider Juliette Berangere Audet bought 1,104 shares of the stock in a transaction on Thursday, September 26th. The shares were bought at an average cost of $15.70 per share, with a total value of $17,332.80. Following the purchase, the insider now owns 1,104 shares of the company’s stock, valued at $17,332.80. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
NewAmsterdam Pharma Trading Up 4.2 %
Shares of NewAmsterdam Pharma stock opened at $17.29 on Wednesday. NewAmsterdam Pharma has a 52-week low of $5.63 and a 52-week high of $26.35. The company has a 50 day moving average of $16.50 and a 200 day moving average of $18.92.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.08. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $2.20 million. On average, research analysts predict that NewAmsterdam Pharma will post -2.06 EPS for the current fiscal year.
Institutional Trading of NewAmsterdam Pharma
Wall Street Analyst Weigh In
Several research analysts have recently commented on the stock. Needham & Company LLC assumed coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, August 28th. They issued a “buy” rating and a $36.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $33.80.
Get Our Latest Stock Report on NewAmsterdam Pharma
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What is a SEC Filing?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.